60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Short Interest Update

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) was the target of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 87,000 shares, a growth of 133.2% from the October 31st total of 37,300 shares. Approximately 5.6% of the company’s stock are sold short. Based on an average daily trading volume, of 91,900 shares, the days-to-cover ratio is presently 0.9 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research report on Friday, November 15th.

60 Degrees Pharmaceuticals Trading Down 2.8 %

Shares of 60 Degrees Pharmaceuticals stock traded down $0.03 during trading on Friday, reaching $1.06. The company’s stock had a trading volume of 22,842 shares, compared to its average volume of 240,494. The company has a 50-day moving average price of $1.01 and a two-hundred day moving average price of $0.77. The firm has a market cap of $2.43 million, a PE ratio of -0.11 and a beta of 4.78. 60 Degrees Pharmaceuticals has a fifty-two week low of $0.70 and a fifty-two week high of $18.36.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.